Sartorius Stedim Biotech (Sartorius Stedim Biotech) Equity-to-Asset

: 0.34 (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Sartorius Stedim Biotech's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $2,877 Mil. Sartorius Stedim Biotech's Total Assets for the quarter that ended in Dec. 2023 was $8,440 Mil. Therefore, Sartorius Stedim Biotech's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.34.

The historical rank and industry rank for Sartorius Stedim Biotech's Equity-to-Asset or its related term are showing as below:

SDMHF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.34 Med: 0.59 Max: 0.66
Current: 0.34

During the past 13 years, the highest Equity to Asset Ratio of Sartorius Stedim Biotech was 0.66. The lowest was 0.34. And the median was 0.59.

SDMHF's Equity-to-Asset is ranked worse than
82.53% of 870 companies
in the Medical Devices & Instruments industry
Industry Median: 0.65 vs SDMHF: 0.34

Sartorius Stedim Biotech Equity-to-Asset Historical Data

The historical data trend for Sartorius Stedim Biotech's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sartorius Stedim Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

Get a 7-Day Free Trial

0.63

0.50

0.42

0.48

0.34

Sartorius Stedim Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial															0.48	0.48	0.50	0.33	0.34

Competitive Comparison

For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sartorius Stedim Biotech Equity-to-Asset Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Sartorius Stedim Biotech's Equity-to-Asset falls into.

Sartorius Stedim Biotech Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Sartorius Stedim Biotech's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	2876.663	/	8440.458
	=	0.34

Sartorius Stedim Biotech's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	2876.663	/	8440.458
	=	0.34

Sartorius Stedim Biotech (OTCPK:SDMHF) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Sartorius Stedim Biotech Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Sartorius Stedim Biotech's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Sartorius Stedim Biotech (Sartorius Stedim Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sartorius Stedim Biotech SA (OTCPK:SDMHF) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

SRTOY:USA DIM:Mexico DIMp:UK 0RG8:UK DIM:France 56S1:Germany

Address

Otto-Brenner-Strasse 20, Goettingen, DEU, 37079

Website

https://www.sartorius.com

Sartorius Stedim Biotech, or SSB, is a leading provider of bioprocessing solutions. Its sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs, and has a focus on single-use technology, or SUT. It is a subsidiary of Sartorius AG, which has a 74% ownership and 85% voting control. The business is geographically diverse.